This report examines the cytotoxicity of chemotherapeutic agents to primary bone marrow-derived IL-3-dependent cells. Such cells derived from p53-null mice were resistant to almost 100-fold higher concentrations of the inhibitors of deoxyribonucleotide synthesis FUdR, methotrexate and hydroxyurea than cells with wild-type p53. In contrast, the cytotoxicity of the DNA damaging agents X-irradiation, cisplatin or bleomycin was p53-independent. The topoisomerase II inhibitor etoposide induced p53-dependent death, which suggests that DNA damage may not be its primary mechanism of cytotoxicity in this cell type. An IL-3-dependent cell line which expresses wild-type p53 was used to demonstrate that the ability of cytotoxic drugs to increase p53 expression level does not control their ability to induce p53-dependent loss of clonigenicity. Finally, comparison with a p53-null IL-3-dependent cell line was used to show that absence of p53 delays the rate of entry into apoptosis following treatment with either DNA damaging agents or inhibitors of deoxyribonucleotide synthesis. This distinguishes short-term eects of p53 on rate of entry into apoptosis from its role in controlling ultimate cell survival. Oncogene (2000) 19, 3556 ± 3559.
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The p53 protein functions to suppress tumour formation (Srivastava et al., 1990; Donehower et al., 1992) . The p53 gene is frequently mutated in human tumours (Hollenstein et al., 1991) and lack of p53 inhibits stimulation of apoptosis in tumour cells by various cytotoxic drugs (for example Lowe et al., 1993; O'Connor et al., 1997) . This implies that tumour cells must be intrinsically more resistant than proliferating normal cells to chemotherapy by virtue of their lack of functional p53. We have previously tested this hypothesis by examining the role of p53 in the response of normal haematopoietic cells to X-irradiation. In this study we showed that p53-null primary IL-3-dependent cells are as sensitive to X-irradiation as their wild-type counterparts (Silva et al., 1997) . This demonstrated that p53 is not involved in controlling the toxicity of DNA damage in this particular cell type.
We now wished to examine the role of p53 in the cytotoxicity to primary haematopoietic cells of a number of chemotherapeutic agents, as bone marrow is also a target for chemotherapeutic toxicity. To do this we again used primary IL-3-dependent cultures from bone marrow of p53-null mice or normal littermate controls. Such cultures comprise proliferating cells of mast cell phenotype (Silva et al., 1997) and provide a tractable primary cell system in which clonigenicity can readily be assessed. The dose of Xirradiation which was lethal to these cells (Silva et al., 1997) would cause both single strand and double strand DNA breaks (Kemp et al., 1984) . Figure 1a shows that a similar result was obtained with another DNA-damaging agent cisplatin, which causes DNA strand crosslinks (Eastman, 1987) . p53-null and wildtype cells were equally sensitive to cisplatin. However, a striking dierence was observed with the thymidylate synthase inhibitor FUdR, which has also been reported to induce single strand and double strand DNA breaks by depletion of the dTTP pool (Ingraham et al., 1986) . In this case the p53-null cells were resistant to almost 100-fold higher concentrations of FUdR ( Figure 1b and Table 1 ).
To attempt to identify the type of cellular insult which leads to p53-dependent or p53-independent cell death in this cell type, we then examined the action of further cytotoxic drugs. Bleomycin is a glycopeptide antibiotic which binds GC rich regions of DNA and induces both single and double strand DNA breaks. Table 1 shows that p53-null and wild-type cells were also equally sensitive to bleomycin. However, a surprising result was obtained with the topoisomerase II inhibitor etoposide, which is also known to induce both single and double strand DNA breaks (Liu, 1989) . The p53-null cells were considerably more resistant to etoposide, being killed at 100-fold higher concentrations of drug (Table 1 ). The p53-independent death in response to X-irradiation, cisplatin and bleomycin, compared to the p53-dependence of the response to etoposide (Table 1) suggests that the DNAdamaging eects of etoposide may not be its primary mechanism of cytotoxicity in this cell type.
A consistent pattern of p53-dependence was observed when further inhibitors of deoxyribonucleotide synthesis were used. Methotrexate inhibits dihydrofolate reductase, which is required to regenerate tetrahydrofolate, a cofactor for thymidylate synthase activity. Table 1 shows that p53-null cells were resistant to over 100-fold higher concentrations of methotrexate. Hydroxyurea inhibits ribonucleotide reductase, which converts ribonucleotides to deoxyribonucleotides. Again p53-null cells were resistant to over 100-fold higher concentrations of hydroxyurea. Two general conclusions can be drawn from the data of Table 1 .
Firstly, most DNA-damaging agents do not require the action of p53 to kill these IL-3-dependent bone marrow cultures. Note that small dierences in the values calculated for X-irradiation or bleomycin (Table  1) , obtained from graphs similar to those of Figure 1 , were not concluded to be signi®cant. Secondly, the cytotoxic action of inhibitors of deoxyribonucleotide synthesis on these cells is highly p53-dependent. The p53-dependent eect of etoposide remains an exception to these conclusions. However, eects of etoposide on nucleoside transport (Loike and Horwitz, 1976 ) and nucleotide pools (Tanizawa et al., 1989) have been reported, which may explain why it is similar to inhibitors of deoxyribonucleotide synthesis in requiring p53 for eective cytotoxicity. We have previously reported that the cytotoxicity of inhibitors of deoxyribonucleotide synthesis can only be blocked by Bcl-2 over-expression (Oliver et al., 1993; whereas the cytotoxicity of DNA damaging agents is prevented by Bcl-2 over-expression or the presence of IL-3 (Collins et al., 1992; Ascaso et al., 1994) . The data of Table 1 therefore suggest that the presence of IL-3 can only block p53-independent cytotoxicity.
In order to obtain sucient cell numbers for biochemical analysis, we isolated a p53-null cell line by limiting dilution of an IL-3-dependent bone marrow culture. Table 2 shows the response to cytotoxic drugs of this p53-null cell line, Bip-2, compared to the IL-3-dependent cell line Baf-3 which expresses wild-type p53 (Silva et al., 1997) . X-irradiation, cisplatin and bleomycin did not require the action of p53 to kill these cell lines whereas the cytotoxic action of etoposide, methotrexate and FUdR was highly p53-dependent ( Table 2) . The results we obtained with the two cell lines (Table 2) were essentially identical to those with the bone marrow cultures (Table 1) , in terms of p53-dependence of death and levels of drugs required for loss of clonigenicity. We therefore used the wildtype p53 cell line Baf-3 to assess the ability of the cytotoxic drugs to increase p53 expression. Both the DNA-damaging treatments (X-irradiation, cisplatin and etoposide) and the inhibitors of deoxyribonucleotide synthesis (methotrexate and FUdR) that we assayed increased the level of p53. Figure 2 shows Figure 1 Role of p53 in sensitivity of IL-3-dependent bone marrow cells to chemotherapeutic agents. Bone marrow was aspirated from the femurs of p53-null mice or normal littermate controls (C57B1/6-Trp53-tm1Tyj, kindly provided by Dr BudhramMahadeo), then cultured for 14 ± 21 days in DMEM/10% FBS with 2% WEHI-3B conditioned medium as a source of IL-3. At this point the cultures represent 490% IL-3-dependent mast cells, as previously described (Silva et al., 1997) . The plating eciency of cultures from p53-null mice or normal littermate controls was measured after various levels of cisplatin (24 h exposure) or FUdR (continuous exposure), by plating serial twofold dilutions of cells in 96 well plates, starting at 2500 cells per well, with 8 wells plated at each dilution. The lowest dilution of cells at which less than 30% of wells were positive by microscopic inspection (minimum of 100 cells) after 7 ± 10 days was used to determine plating eciency at each drug concentration. This was then expressed as a fraction of the plating eciency in the absence of drug. Values shown are the mean+standard error of duplicate determinations performed with independent cultures. In the absence of treatment the plating eciencies of the cultures varied between 3 ± 10% (wild-type) and 2.5 ± 17% (p53-null) *The plating eciency of IL-3-dependent bone marrow cultures from p53-null mice or normal littermate controls was measured after various levels of X-irradiation (Pantac X-ray machine with an output of 240 KeV at a dose rate of 3 ± 4 Gy/min); cisplatin, bleomycin or etoposide (24 h exposure); hydroxyurea, methotrexate or FUdR (continuous exposure), as described in Figure 1 . In each case the dose required to induce a 50% loss of clonigenicity was determined from graphs similar to those of Figure 1 Oncogene The role of p53 in death of IL-3-dependent cells C Palacios et al typical induction by X-irradiation, cisplatin and methotrexate 24 h after treatment. This increase in level of p53 after DNA damage or inhibition of deoxyribonucleotide synthesis has been described in many cell types (for example Tishler et al., 1993; Nelson and Kastan, 1994) and has been demonstrated, in some cases, to be due to increased p53 protein stability. From our results we can conclude that the ability of cytotoxic drugs to increase the level of p53 does not control their ability to induce p53-dependent loss of clonigenicity, in agreement with previous observations (Bunz et al., 1999) . In our previous study on the eects of X-irradiation we reported that p53 increased the rate of entry into apoptosis in the absence of IL-3 (Silva et al., 1997) . We therefore examined the rate of entry into apoptosis of Baf-3 and Bip-2 cells deprived of IL-3, or deprived of IL-3 in the presence of sub-lethal doses of cisplatin or bleomycin. Table 3 shows that apoptosis of Bip-2 cells was delayed under these conditions compared to that of Baf-3 cells. A delay in apoptosis following IL-3 removal has also been described when the function of p53 is inhibited by a dominant interfering mutant (Gottlieb et al., 1994) . We also examined the rate of entry into apoptosis of Baf-3 and Bip-2 cells in the presence of IL-3 and lethal concentration of methotrexate and FUdR. Table 4 shows that p53 also controlled the rate of entry into apoptosis under these conditions.
Measurement of apoptosis in cell cultures following cytotoxic treatment, without a subsequent assessment of clonigenicity, will document eects of p53 on the rate of entry into apoptosis but not on ultimate cell survival (Clarke et al., 1993; Lowe et al., 1993) . The discrepancy between these two measurements has been noted previously (Lamb and Friend, 1997) . In fact irradiation of p53 7/7 embryos reveals an increased slow apoptototic response in the absence of p53 (Frenkel et al., 1999) . A study which measured clonigenicity after cisplatin treatment in teratocarcinoma cells reported that p53
7/7 cells did not rapidly enter apoptosis, but that their ultimate survival was identical to p53 +/+ cells (Zamble et al., 1998) ; this is very similar to the results reported here. However, in other cell types clearly dierent responses have been described. For example, embryonic stem cells undergo p53-independent apoptosis in response to both DNA damage and inhibition of deoxyribonucleotide synthesis (Aladjem et al., 1998) and B cell precursors show a p53-dependent loss of ) (Palacios and Steinmetz, 1985) and Bip-2 (p53
), cloned by limiting dilution from a p53-null IL-3-dependent bone marrow culture, were cultured in RPMI/10% FBS with 2% WEHI-3B conditioned medium as a source of IL-3. The surviving fraction of cells was determined after various levels of X-irradiation or 24 h exposure to various levels of cisplatin, bleomycin, etoposide, methotrexate or FUdR, as described in Figure 1 . In the absence of treatment the plating eciencies of the cell lines were 70% (Baf-3) and 43% (Bip-2) Figure 2 Increased p53 levels in response to chemotherapeutic agents. The IL-3-dependent, p53 +/+ , cell line Baf-3 was Xirradiated, or treated with the concentration of cisplatin or methotrexate shown. After 24 h, cells were pelleted and resuspended in reducing SDS ± PAGE sample buer, then heated to 1008C. 5610 5 cells per track were then run on a 10% gel, transferred to Immobilon-P (Millipore) and probed with antibodies Ab-7 against p53 (Calbiochem) and DM1A against tubulin (Sigma). The secondary antibody were anti-sheep-HRP and antimouse-HRP respectively (Dako) and the blots were developed with ECL ) were deprived of IL-3 and treated with cisplatin or bleomycin as shown. At the times indicated cells in a sub-G1 peak, representing apoptotic cells, were quantitated as a percentage of total cells. Brie¯y, 10 6 cells were suspended in 200 ml PBS and ®xed with 2 ml of ice-cold 70% ethanol/30% PBS. Fixed cells were pelleted, resuspended in PBS, then incubated for 30 min with 100 mg/ml ribonuclease and 40 mg/ml propidium iodide. The¯uorescence of stained cells was analysed using a FACScan; subdiploid cells were used as a measure of apoptotic cells. Data from a single representative experiment of three is shown ) were treated with methotrexate or FUdR in the presence of IL-3. At the times indicated cells were stained with propidium iodide to measure DNA content, as described in Table 3 . Data from a single representative experiment of three is shown clonigenicity in response to X-irradiation (Griths et al., 1997) .
Our conclusion, using IL-3-dependent cell cultures, that p53 is important for the response to FUdR is supported by experiments in mice. Intestinal crypt damage was observed in p53 +/+ mice, but not in p53 7/7 mice, following FUdR administration (Pritchard et al., 1998) . p53 7/7 mice also showed faster haematopoietic recovery than p53 +/+ mice following FUdR administration (Wlodarski et al., 1998) . In this report we also concluded that the clonigenicity of IL-3-dependent cell cultures following DNA damage is not controlled by p53. This suggests that an alternative pathway, such as the c-Abl/p73 response (Agami et al., 1999; Gong et al., 1999) , is involved in the response of IL-3-dependent cells to DNA damage.
